Stockreport

Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics plc - Ordinary Share  (ITRM) 
Last iterum therapeutics plc - ordinary share earnings: 11/12 04:30 pm Check Earnings Report
PDF ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades --Company to Host Conference [Read more]